Longboard Pharmaceuticals (LBPH) Stock Price, News & Analysis

Company Overview

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

Key Stats

• Today's Range: $59.71 to $59.86
• 50-Day Range: $27.58 to $59.81
• 52-Week Range: $3.60 to $59.95
• Volume: 660,102 shs
• Average Volume: 3.83 million shs
• Market Capitalization: $2.33 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $59.56
• Consensus Rating: Hold

Longboard Pharmaceuticals Stock Analysis - MarketRank™

Longboard Pharmaceuticals scored higher than 27% of companies evaluated by MarketBeat, and ranked 825th out of 969 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.2 / 5
• Analyst Rating: Hold

Consensus Rating

Longboard Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 4 buy ratings, 5 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Longboard Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Longboard Pharmaceuticals are expected to decrease in the coming year, from ($2.19) to ($2.80) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Longboard Pharmaceuticals is -27.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Longboard Pharmaceuticals is -27.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Longboard Pharmaceuticals has a P/B Ratio of 35.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

15.34% of the float of Longboard Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Longboard Pharmaceuticals has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Longboard Pharmaceuticals has recently decreased by 3.90%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Longboard Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Longboard Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.34% of the float of Longboard Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Longboard Pharmaceuticals has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Longboard Pharmaceuticals has recently decreased by 3.90%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: -0.10

News Sentiment

Longboard Pharmaceuticals has a news sentiment score of -0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.37 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Longboard Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

Only 7 people have searched for LBPH on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.

MarketBeat Follows

6 people have added Longboard Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Longboard Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,090,010.00 in company stock.

Percentage Held by Insiders

Only 4.64% of the stock of Longboard Pharmaceuticals is held by insiders.

Percentage Held by Institutions

63.28% of the stock of Longboard Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LBPH Stock Analysis - Frequently Asked Questions

How have LBPH shares performed this year?

Longboard Pharmaceuticals' stock was trading at $6.03 at the start of the year. Since then, LBPH shares have increased by 891.9% and is now trading at $59.81.
View the best growth stocks for 2024 here.

How were Longboard Pharmaceuticals' earnings last quarter?

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) issued its earnings results on Thursday, November, 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by $0.04.

When did Longboard Pharmaceuticals IPO?

Longboard Pharmaceuticals (LBPH) raised $75 million in an IPO on Friday, March 12th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Evercore ISI, Guggenheim Securities and Cantor served as the underwriters for the IPO.

Who are Longboard Pharmaceuticals' major shareholders?

Longboard Pharmaceuticals' top institutional investors include Jennison Associates LLC (2.36%), Emerald Advisers LLC (1.76%), Emerald Mutual Fund Advisers Trust (1.08%) and Braun Stacey Associates Inc. (0.77%). Insiders that own company stock include Randall Kaye and Arena Pharmaceuticals Inc.
View institutional ownership trends.

How do I buy shares of Longboard Pharmaceuticals?

Shares of LBPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Longboard Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Longboard Pharmaceuticals investors own include JPMorgan Chase & Co. (JPM), Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Visa (V) and Home Depot (HD).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 11/10/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/11/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LBPH
• CUSIP: N/A
• CIK: 1832168
• Web: www.longboardpharma.com
• Phone: 619-592-9775
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $59.56
• High Stock Price Target: $90.00
• Low Stock Price Target: $32.00
• Potential Upside/Downside: -0.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.44
• Research Coverage: 9 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-54,420,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -36.93%
• Return on Assets: -34.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 20.95
• Quick Ratio: 20.95

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.67 per share
• Price / Book: 35.81

Miscellaneous

• Outstanding Shares: 38,900,000
• Free Float: 37,095,000
• Market Cap: $2.33 billion
• Optionable: Optionable
• Beta: 1.07